

# Fiorella Ilariucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4444608/publications.pdf>

Version: 2024-02-01

59  
papers

3,220  
citations

201674

27  
h-index

175258

52  
g-index

59  
all docs

59  
docs citations

59  
times ranked

3695  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	7.2	47
2	MATRixâ€“RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e110-e121.	4.6	54
3	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-9.	1.8	3
4	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€“world setting. A GIMEMAâ€“ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	2.8	12
5	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	3.5	30
6	Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. <i>European Journal of Haematology</i> , 2018, 101, 78-85.	2.2	5
7	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	1.8	12
8	R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial. <i>Blood</i> , 2018, 132, 1687-1687.	1.4	0
9	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	4.6	258
10	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	1.6	94
11	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016, 60, 154-165.	2.8	22
12	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€“CLLâ€“GISEL study. <i>European Journal of Haematology</i> , 2016, 96, 36-45.	2.2	7
13	Reduced intensity <sc>VEPEMB</sc> regimen compared with standard <sc>ABVD</sc> in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (<sc>FIL</sc>). <i>British Journal of Haematology</i> , 2016, 172, 879-888.	2.5	29
14	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	1.3	30
15	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. <i>Blood</i> , 2016, 128, 511-511.	1.4	13
16	Integrating Oncogeriatric Tools into the Management of Chronic Lymphocytic Leukemia: Current State of the Art and Challenges for the Future. <i>Current Oncology Reports</i> , 2015, 17, 31.	4.0	3
17	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. <i>Leukemia Research</i> , 2015, 39, 840-845.	0.8	12
18	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. <i>British Journal of Haematology</i> , 2015, 168, 455-459.	2.5	9

#	ARTICLE	IF	CITATIONS
19	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. <i>Blood</i> , 2015, 126, 2946-2946.	1.4	1
20	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. <i>PLoS ONE</i> , 2015, 10, e0118801.	2.5	15
21	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter Oâ€CLL1â€GISL study. <i>American Journal of Hematology</i> , 2014, 89, 743-750.	4.1	14
22	MATILDE chemotherapy regimen for primary CNS lymphoma. <i>Neurology</i> , 2014, 82, 1370-1373.	1.1	38
23	Highâ€throughput sequencing for the identification of <i><sc>NOTCH</sc>1</i> mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. <i>British Journal of Haematology</i> , 2014, 165, 629-639.	2.5	52
24	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2014, 124, 3074-3074.	1.4	1
25	Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. <i>Blood</i> , 2014, 124, 3088-3088.	1.4	3
26	Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2014, 124, 499-499.	1.4	1
27	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8507-8507.	1.6	5
28	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3314-3314.	1.4	0
29	Total body computed tomography scan in the initial workâ€up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. <i>American Journal of Hematology</i> , 2013, 88, 539-544.	4.1	10
30	Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (Râ€E regimen) in patients with primary CNS lymphoma relapsed or refractory to highâ€dose methotrexateâ€based chemotherapy. <i>Hematological Oncology</i> , 2013, 31, 143-150.	1.7	66
31	Chromosome 2p gain in monoclonal Bâ€cell lymphocytosis and in early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 24-31.	4.1	27
32	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. <i>Clinical Cancer Research</i> , 2013, 19, 5890-5900.	7.0	60
33	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). <i>Blood</i> , 2013, 122, 3049-3049.	1.4	2
34	High-Throughput Sequencing For The Identification Of NOTCH1 mutations In Early Stage Chronic Lymphocytic Leukemia: Biological and Clinical Implications. <i>Blood</i> , 2013, 122, 1622-1622.	1.4	0
35	Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012, 120, 3858-3860.	1.4	58
36	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly â€fitâ€ patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012, 53, 581-588.	1.3	74

#	ARTICLE	IF	CITATIONS
37	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012, 156, 346-353.	2.5	122
38	An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 4079-4085.	1.4	28
39	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2011, 6, e24313.	2.5	36
40	Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. <i>Leukemia Research</i> , 2010, 34, 312-321.	0.8	48
41	Enteropathy-associated T cell lymphoma of the jejunum associated with colonic lymphocytosis with aberrant phenotype. <i>Journal of Clinical Pathology</i> , 2010, 63, 850-852.	2.0	0
42	Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study. <i>Blood</i> , 2010, 116, 1384-1384.	1.4	0
43	Incidence Rate of Thromboembolic Events (TE) In a Prospectively Evaluated Population of Patients with Lymphoma Enrolled In First Line Treatment Clinical Trials: a Report From the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Blood</i> , 2010, 116, 4208-4208.	1.4	0
44	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009, 115, 1906-1913.	4.1	6
45	Ocular involvement in nasal natural killer T-cell lymphoma. <i>International Ophthalmology</i> , 2009, 29, 275-279.	1.4	39
46	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	2.5	106
47	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009, 374, 1512-1520.	13.7	588
48	Temozolomide as salvage treatment in primary brain lymphomas. <i>British Journal of Cancer</i> , 2007, 96, 864-867.	6.4	135
49	R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2007, 110, 3429-3429.	1.4	1
50	Defibrotide Low-Dose Continuous Infusion from Day +1 Until Day +21 after Allogeneic Stem Cell Transplantation as Prophylaxis of Veno-Occlusive Disease (VOD) of the Liver. A Single Centre Experience.. <i>Blood</i> , 2007, 110, 4927-4927.	1.4	3
51	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , 2007, 110, 3089-3089.	1.4	0
52	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.	1.1	83
53	Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenström's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System. <i>Journal of Clinical Oncology</i> , 2005, 23, 4662-4668.	1.6	73
54	Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 424-431.	1.6	134

#	ARTICLE	IF	CITATIONS
55	Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. <i>Annals of Oncology</i> , 2004, 15, 1215-1221.	1.2	111
56	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the "cutaneous variant" <sup>1</sup> . <i>British Journal of Haematology</i> , 2004, 127, 173-183.	2.5	535
57	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas. <i>Cancer</i> , 2004, 101, 1601-1608.	4.1	40
58	Bleomycin, Etoposide, Cyclophosphamide, Vincristine and Prednisone (BACOP) in Patients with Follicular Non-Hodgkin's Lymphoma: Results of a Prospective, Multicenter Study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Leukemia and Lymphoma</i> , 2002, 43, 1795-1801.	1.3	6
59	Image-Aided Estimate of Tumor Burden in Hodgkin's Disease: Evidence of Its Primary Prognostic Importance. <i>Journal of Clinical Oncology</i> , 2001, 19, 1388-1394.	1.6	59